Interim results of the study have been presented previously at the ISPOR Annual European Congress in Amsterdam, 2014. 3 For the current analysis, the final sample was classified into groups of 'accepting', 'ambivalent', 'sceptical', and 'indifferent' patients according to a modified version of the 'Beliefs about Medicines Questionnaire' (BMQ). 4 Part-worth utilities (preference weights) of attribute levels were assessed by paired model regression analysis. 5 Adjusted overall regression analysis was computed while controlling for patient beliefs and further potentially confounding patientrelated variables. To assess the exact effect of patient beliefs, an additional subgroup regression analysis was performed calculating b-weights for each group separately.
Results

N=1
,588 patients from 44 rheumatologists completed the DCE. The majority of patients were female (74%), 50 to 64 years of age (45%), reported ,10 years of disease duration (54%) and mild to moderate disease activity (63%). The vast majority were receiving DMARDs (98%) and reported that they were satisfied with their current treatment (84%) -54% were receiving injectables, 43% were being administered exclusively oral DMARDs; with regard to other medication, overall, 57% were currently receiving an injectable.
According to the modified BMQ, most patients were classified as 'accepting' or 'ambivalent' (both characterised by low concern regarding their current medication) ( Table 1) .
Adjusted regression results (see Figure 2 ) yielded 'mode of administration' to be the most important attribute with 'oral application' being most desired (highest positive b in regression analysis) and 'intravenous (iv) infusion' being most strongly rejected (highest negative b in regression analysis). The second most relevant attribute was 'necessity of combination therapy with MTX' ('no combination' being preferred), followed by 'frequency of administration' ('every 1 to 2 weeks' being most strongly rejected), 'side effects' ('allergic reactions' being accepted and 'deterioration of laboratory values' being rejected most often) and 'time to onset of effect' ('up to one month' being preferred over 'up to three months').
There was a significant effect of patient beliefs on preferences while controlling for further important patient-related variables (see Table 2 ).
Subgroup regression analysis yielded statistically relevant differences (in terms of non-overlapping confidence intervals) for 'mode of administration' and 'tolerance of side effects' (see Figure 3 , red boxes). Patients defined as 'sceptical' showed stronger rejection (more negative b-weight) of 'subcutaneous (sc) self-injection' than patients defined as 'accepting' or 'indifferent.' Moreover, solely 'sceptical' patients showed rejection of 'infections.'
Conclusions
Results indicate that patient beliefs are meaningfully associated with patient preferences regarding treatment characteristics.
While RA patients with an 'accepting' or 'indifferent' attitude (both characterised by low concern regarding their current medication) do not mind having to inject themselves and readily accept the risk of infections posed by DMARDs, for 'sceptical' patients (characterised by high concern regarding their current medication), these aspects are viewed as negative.
This may offer important leads to improving adherence in chronic diseases by designing more consumer-friendly pharmaceutical products tailored to different subgroups of patients. 
Patient beliefs and preferences in treatment with disease-modifying antirheumatic drugs
Mode of administration
Treatment 2 Treatment 3
Subcutaneous self-injection
Intravenous infusion Pill
Frequency of administration
Once every 6-12 months 
